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Background/Aim. Myeloid-derived suppressor cells 
(MDSCs) suppress immune responses via a series of 
inhibitory mechanisms, which ultimately could lead to 
tumor growth. B7-H4 expression is significantly associated 
with poor outcome and promotion of tumor cell 
proliferation, invasion and migration in patients with 
various cancers. Data concerning B7-H4 expression in lung 
cancers (LC), either on tumor or immunological cells, are 
still sporadic. The aim was to estimate and correlate the 
number of CD14+B7-H4+MDSCs in blood and lung tumor 
microcirculation with clinical stage, histology type of tumor, 
tumor node metastasis (TNM) stadium, nodal status and 
disease outspread. Methods. The study included 44 lung 
cancer patients (III and IV clinical stage) and 30 healthy 
controls. CD14+B7-H4+ MDSC number was estimated by 
flow cytometry in blood and tumor microcirculation 
samples of each patient. Results.  CD14+B7-H4+ MDSCs 
number was significantly higher in patients’ samples 
compared to controls. CD14+B7-H4+ MDSC number was 
significantly increased in tumor compared to blood sample 
of the same patient. Clinical stage III patients had the 
increased number of the CD14+B7-H4+ MDSC compared 
to stage IV, in both types of samples. According to 
histology, small cell lung cancer (SCLC) patients had the 
highest average CD14+B7-H4+ MDSCs number, 
significantly increased compared to patients with squamous 
and large cell LC histology type. Tumor size was directly 
associated with the number of the CD14+B7-H4+ MDSC, 
both in blood and tumor samples. Furthermore, nodal 
involvement was associated with the gradual increase of the 
CD14+B7-H4+ MDSC number, being the highest in the N3 
group, again both in blood and tumor samples. Finally, we 
detected higher CD14+B7-H4+ MDSCs number in the 
samples of patients without metastases. Conclusion. 
CD14+B7-H4+ MDSCs number in LC patients is 
significantly associated with tumor histology type, lymph 
node involvement, disease extent degree and tumor size. 
Concerning their large number in LC tumor 
microenvironment together with immunosuppressive 
capacities, CD14+B7-H4+ MDSCs could represent 
important tumor promoting factor in LC pathophysiology.  
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Uvod/Cilj. Mijeloidne supresorske ćelije [myeolid derived 
suppressor cells (MDSCs)] negativno regulišu imunski odgovor 
nizom inhibitornih mehanizama koji konačno omogućavaju 
rast tumora. Ispoljavanje B7-H4 je značajno povezano sa 
lošim ishodom, kao i promocijom proliferacije, invazije i 
migracije ćelija tumora kod bolesnika sa različitim tipovima 
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karcinoma. Podaci koji prikazuju ispoljavanje B7-H4 u 
tumorima pluća, na tumorskim ili imunskim ćelijama, su i dalje 
retki. Cilj rada bio je utvrditi i korelirati zastupljenost 
CD14+B7-H4+ ćelija sličnih MDSCs (CD14+B7-H4+ MDSCs) 
u krvi i mikrocirkulaciji tumora pluća sa kliničkim stadijumom, 
histološkim tipom tumora, tumor nodus metastaza (TNM) 
stadijumom, nodalnim statusom i raširenošću bolesti. Metode. 
U studiju je bilo uključeno 44 bolesnika sa karcinomom pluća 
(III i IV klinički stadijum) i 30 zdravih osoba. Zastupljenost (%) 
CD14+B7-H4+ MDSCs je bila utvrđena protočnom 
citometrijom u krvi i mikrocirkulaciji tumora svakog bolesnika. 
Rezultati. Zastupljenost  CD14+B7-H4+ MDSCs bila je 
značajno veća u uzorcima bolesnika u odnosu na kontrole. 
CD14+B7-H4+ MDSCs u uzorku tumora su bile značajno 
brojnije u odnosu na uzorak krvi istog bolesnika. Bolesnici III 
kliničkog stadijuma imali su povećane vrednosti CD14+B7-H4+ 
MDSCs u odnosu na one u IV stadijumu, u obe vrste uzoraka. 
Prema histološkom tipu, bolesnici sa sitnoćelijskim 
karcinomom pluća imali su najveće vrednosti CD14+B7-H4+ 
MDSCs, značajno povećane u odnosu na bolesnike sa 
skvamoznim ili giganto-ćelijskim tipom tumora. Veličina 
tumora bila je direktno udružena sa brojem CD14+B7-H4+ 
MDSCs, u obe vrste uzoraka. Zahvaćenost limfnih žlezda bila 
je udružena sa postepenim povećanjem vrednosti CD14+B7-
H4+ MDSCs, sa najvećim vrednostima u N3 grupi, u obe vrste 
uzoraka. Na kraju, detektovali smo veće vrednosti CD14+B7-
H4+MDSCs u uzorcima bolesnika bez metastaza. Zaključak. 
Vrednosti CD14+B7-H4+ MDSCs kod bolesnika sa 
karcinomom pluća značajno su povezane sa histološkim tipom 
tumora, zahvatanjem limfnih čvorova, stepenom raširenosti 
bolesti i veličinom tumora. S obzirom na visoke vrednosti u 
mikrookruženju tumora pluća zajedno sa njihovim 
imunosupresivnim kapacitetima, CD14+B7-H4+ MDSCs mogu 
predstavljati važan promovišući faktor u patofiziologiji 
karcinoma pluća.  
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Lung cancer (LC) is the most common carcinoma in 
men while in women it is the fourth most common 
malignancy, and the second by lethal outcome 1. At the 
moment of diagnosis, more than 50% of patients are in a 
locally advanced stage or have distant metastases, with 
poor five-year survival even in patients with localized 
disease. 
Focus of contemporary immunotherapy is tumor-
mediated immune suppression and modulation of tumor 
specific T lymphocyte activity by acting on checkpoint 
immune inhibitors. Beside programmed death (PD-1), PD-1 
ligand and CTLA-4, new data describe other members of B7 
accessory molecules that critically regulate activation or 
suppression of T lymphocytes 2. Among them, B7-H4 
(B7S1, B7x, Vtcn1) is a strong inhibitor of T cell activity 3. 
Investigation of B7-H4 mRNA demonstrated broad presence 
in human non-lymphoid tissues. Expression of B7-H4 is 
documented in various solid malignant tumors, and its 
presence on tumor cells is associated with the increased rate 
of proliferation, metastasis and unfavorable outcome in 
patients with kidney cancer, oral and esophageal squamous 
carcinoma, gastric and LC 2. Sica et al. 3 and Prasad et al. 4 
were among first that demonstrated that B7-H4 expression is 
not restricted to tumor cells. They described that in vitro 
stimulation induced B7-H4 expression on population of T 
lymphocytes, majority of B lymphocytes and 
monocytes/macrophages. Macrophages isolated from ovarian 
cancer or from ascites of patients with ovarian cancer 
demonstrated significant expression of B7-H4 and potently 
inhibited in vitro T lymphocyte activation 5. Furthermore, 
B7-H4 expression and suppressive capacity could be 
stimulated on macrophages after incubation with interleukin 
(IL)-10 and IL-6 6. Recently, these suppressive population of 
B7-H4 macrophages have been demonstrated in patients with 
glioma 7. Li et al. 8 investigated possible mechanisms 
involved in generation of exhausted CD8+ tumor infiltrating 
T lymphocytes in patients with hepatocellular carcinoma. 
They showed that the expression of B7-H4 on myeloid cells 
in tumor is in direct correlation with inhibition of CD8+ T 
lymphocytes activity. 
Myeloid-derived suppressive cells (MDSCs) represent 
significant force that supports tumor in survival, proliferation 
and metastasis. Experimental models strongly support 
significant role of MDSCs in immunosuppressive balance 
that favors survival and growth of lung tumors 9. Inefficiency 
of recent trials with inhibitors of immune checkpoint in 
patients with non-small cell lung carcinoma (NSC-LC) is 
explained to be a consequence of significant 
immunosuppressive state caused by MDSCs activity 10. 
Patients with NSC-LC demonstrate high numbers of both 
monocytic and polymorphonuclear MDSCs in peripheral 
circulation and tumor tissue 11. MDSCs number directly 
correlate with inflammatory cytokines concentration, both 
locally and systemically, and the majority of MDSCs express 
PD-L1 as phenotypic marker of high immunosuppressive 
capacity. Yamauchi et al. 11 demonstrated that frequency of 
MDSCs is significantly correlated with the disease course 
and outcome in their cohort of NSC-LC patients. PD-L1 is 
not the only immunosuppressive molecule detected on 
MDSCs in LC patients. Zhang et al. 12 identified two 
populations of MDSCs in tumor tissue of NSC-LC patients 
according to the presence of inhibitory B7-H3 molecule. 
Monocyte like MDSCs population (HLA-DR-/low, 
CD14+MDSC) that expresses B7-H3 is highly 
immunosuppressive, produces significant amounts of IL-10 
and tumor necrosis factor (TNF)-α and the increase of their 
number is significantly associated with short disease free 
interval. Considering all these data, in our study we wanted 
to investigate MDSCs population that express B7-H4 in LC 
patients, another inhibitory molecule, and to analyze 
association of their value with pathological and clinical 
parameters. 
Vol. 78, No 6 VOJNOSANITETSKI PREGLED Page 601 
Vuković J, et al. Vojnosanit Pregl 2021; 78(6): 599–606. 
Methods 
Patients 
The study enrolled 44 patients with diagnosed LC (33 
males 11 females, 62 ± 8 years) and 30 healthy controls (22 
males, 8 females, 57 ± 14 years). Patients were diagnosed 
and treated at the Clinic for Pulmonology, Military Medical 
Academy in Belgrade, Serbia, in 18-month-long period. All 
necessary diagnostic procedures (laboratory, radiological, 
bronchoscopy and histological) were carried out at the 
Military Medical Academy in Belgrade, Serbia. All the 
patients as well as healthy controls signed the Informed 
consent for participation in the research. This study was 
approved by the Ethics Committee of the Military Medical 
Academy in Belgrade, Serbia (12-02/2015). 
Samples 
Blood samples were taken from the cubital vein upon 
admission to the hospital, while tumor microcirculation 
samples were taken by needle biopsy from available 
pathological tumor blood vessels in the course of diagnostic 
bronchoscopy. Samples were taken in vacutainer tubes with 
K2EDTA and erythrocytes removed using the lysing buffer 
(NH4Cl, EDTA, KHCO3) for 10 min with constant mixing. 
The remaining nucleated cells were washed two times with 
the RPMI 1640 culture medium complemented with 5% of 
normal human serum, centrifuged, resuspended, enumerated 
(Beckman Coulter ACT differ blood counter) and 
concentration was corrected to final suspension of 1×106 
cells/100 µL per test tube. 
Cells immunophenotyping 
Final cell suspensions were stained with coctail of 
monoclonal antibodies, as Stanojević et al. 13 did in the 
previous study. Multicolor analysis was performed with 
different combinations of CD15-FITC or PECy7, CD33-
PE or PECy7, CD45-ECD or PECy5, HLA-DR PE/Cy5, 
CD14-FITC, CD16-PE, CD11b-PE, CD10-PECy7, CD3-
FITC, CD19-FITC, CD56-FITC, B7-H4-PECy7 
(Biolegend, USA). The flow cytometry was performed 
using a Beckman Coulter FC 500 flow cytometer with 
CXP analysis software. MDSCs subpopulation was 
identified from the initial CD45+/Side Scatter cell 
population, which was negative for T, B and NK antigens. 
This triple negative population of every sample was 
further gated on a CD11b versus HLA-DR dot plot 
histograme, and MDSCs were analyzed as lineage triple 
negative (CD3-, CD19-, CD56-), CD45+, HLA-DR-/low, 
CD11b+ and CD33low population. After further 
classification of this population according to the 
expression of CD15 or CD14, CD14+ MDSCs population 
was further investigated for B7-H4 expression. The value 
of MDSCs CD14+ B7-H4+ cell population was expressed 
as % of all CD45+ analyzed cells, as we did in our 
previous work 13. 
Statistical analysis 
Data analysis was performed using the GraphPad Prism 5 
software. Comparison between multiple groups was done with 
nonparametric Kruskal–Wallis test, while identification of 
differences was performed with Dunn`s multiple comparison 
test. Difference between average values of two investigated 
groups was analysed with Mann Whitney (MW) test, while 
statistical significance of serial samples (blood/tumor 
microcirculation) of patients was analysed with Wilcoxon (W) 
matched pairs test.  
Results 
Lung cancer patients had significantly higher number 
of the CD14+ B7-H4+MDSCs than controls 
A statistically significant number of CD14+B7-H4+ 
MDSCs was detected in samples of peripheral blood of LC 
patients as well as in tumor microcirculation compared to 
peripheral blood samples of control patients (p = 0.0417, MW 
test). Generally, all patients (excluding 3 that had values as 
healthy controls) demonstrated significantly higher number of 
CD14+B7-H4+ MDSCs in tumor microcirculation samples 
compared to their blood values, either after comparison of 
average number (p = 0.0002, MW test) or when assessing 
particular tumor/blood samples of each patient (p = 0.0000, W 
test) (Table 1). 
Clinical stage III patients had insignificantly increased 
the number of the CD14+B7-H4+ MDSCs compared to 
clinical stage IV patients 
Comparison of patients between the III and the IV 
clinical stage demonstrated no significant difference, either 
in blood or tumor microcirculation samples (Table 1). Again, 
all patients, in both clinical stages had significantly more of 
the CD14+B7-H4+ MDSCs in their correspondive tumor 
microcirculation than blood samples (Table 2). 
Patients with small cell LC histology demonstrated the 
highest average CD14+ B7-H4+MDSC values in tumor 
microcirculation samples 
Stratification of patients in groups related to histological 
type of the tumor revealed differences in CD14+B7-H4+ MDSCs 
number according to different histology. Although all groups 
had more CD14+B7-H4+ MDSCs in their tumor compartment 
compared to blood, these differences reached statistical 
significance for small cell LC, adenocarcinoma and squamous 
LC, but not for patients with large cell LC (Table 2, W test). 
Furthermore, analysis of the average CD14+B7-H4+ MDSCs 
number in tumor/blood compartment demonstrated significant 
increase only in tumor microcirculation of small cell LC and 
squamous cell LC groups (Table 2, MW test). Comparison 
between groups of patients with different lung cancer histology 
type in blood samples revealed no statistical significance, 
although, again, almost all patients had values higher than 
normal controls. But, analysis of tumor microcirculation 
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samples demonstrated that patients with small cell LC had the 
highest average CD14+B7-H4+ MDSC number, significantly 
increased compared to patients with squamous and large cell LC 
histology (Table 3, MW test).  
Smallest tumors are significantly associated with the 
lowest CD14+B7-H4+ MDSC number 
Blood samples of the LC patients with the smallest 
tumors (T1) demonstrated significantly low CD14+B7-H4+ 
MDSCs value, close to the number of healthy controls 
(Table 1). The increment of the tumor was significantly 
associated with the increase of CD14+B7-H4+ MDSCs 
number, compared to this group (T2 > T1, T3 > T1, 
T4 > T1, Table 3, blood, MW test). Interestingly, patients 
with T3 tumors had significantly increased number of the 
CD14+B7-H4+ MDSCs compared to those with the largest 
tumors (T3 > T4, Table 3, MW test). Analysis of tumor 
microcirculation compartment demonstrated almost the 
same relations as in blood, meaning that the patients with 
Table 1  
Presentation of CD14+B7-H4+ MDSCs in blood and  
tumor microcirculation samples of lung cancer (LC) patients  
according to clinical status and tumor characteristics 
Parameter MDSCs (% of total CD45
+ cells), mean ± SD 
blood tumor microcirculation 
Clinical stage   
   III (n = 27) 5.96 ±5.42 26.93 ± 22.03 
   IV (n = 17) 5.38 ± 4.72 23.94 ± 21.28 
Histology type of LC   
   Ad NSCLC (n = 13) 4.40 ± 4.88 24.10 ± 30.05 
   Sq NSCLC (n = 11) 7.50 ± 5.63 26.83 ± 20.31 
   Lc NSCLC (n = 10) 6.00 ± 5.15 9.40 ± 9.86 
   SCLC (n = 10) 6.10 ± 5.78 41.56 ± 9.45 
Tumor size   
   T1 (n = 11) 1.46 ± 1.37 6.82 ± 7.14 
   T2 (n = 13) 7.07 ± 5.44 30.43 ± 23.20 
   T3 (n = 13) 9.29 ± 6.15 28.57 ± 22.62 
   T4 (n = 7) 4.38 ± 2.45 27.00 ± 16.83 
Nodal status   
   N0 (n = 11) 3.00 ± 2.68 7.55 ± 7.83 
   N1 (n = 10) 4.50 ± 2.64 14.50 ± 13.79 
   N2 (n = 13) 7.15 ± 5.98 29.54 ± 21.62 
   N3 (n = 10) 14.67 ± 4.39 33.44 ± 16.27 
Metastases   
   M0 (n = 27) 27 20.43 ± 11.63 
   M1 (n = 17)  17 17.50 ± 3.97 
Note: MDSCs value in blood samples of the control group (n = 30) was 1.04 ± 0.32. 
MDSCs – myeloid-derived suppressive cells;  NSCLC – non small cell lung 
carcinoma; Ad – adenocarcinoma; Sq – squamose; Lc – large cell; SCLC– small 
cell lung carcinoma. 
Table 2 
Comparison of CD14+B7-H4+ MDSCs presentation between blood and tumor microcirculation  
compartments in lung cancer (LC) patients according to clinical status and timor characteristics 
Parameter  Compartment Statistical tests blood tumor microcirculation Mann Whitney Wilcoxon 
Clinical stage III III p = 0.0027 p = 0.0000 
 IV IV p = 0.0122 p = 0.0007 
Histology type SCLC SCLC p = 0.0003 p = 0.0088 
 Ad NSCL Ad NSCLC ns p = 0.0213 
 Sq NSCLC Sq NSCLC p = 0.0025 p = 0.0005 
 Lc NSCLC LC NSCLC ns ns 
Tumor size T1 T1 p = 0.0238 p = 0.0089 
 T2 T2 p = 0.0011 p = 0.0038 
 T3 T3 p = 0.0049 p = 0.0037 
 T4 T4 p = 0.0021 p = 0.0156 
Nodal status N0 N0 p = 0.0362 ns 
 N1 N1 p = 0.0141 p = 0.0112 
 N2 N2 p = 0.0037 p = 0.0126 
 N3 N3 p = 0.0091 p = 0.0017 
Metastases M0 M0 ns p = 0.0028 
 M1 M1 p = 0.0000 p = 0.0025 
For abbreviations see under Table 1. 
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the smallest tumors had significantly less CD14+B7-H4+ 
MDSCs compared to all other groups (T2 > T1, T3 > T1, 
T4 > T1, Table 3, tumor microcirculation, MW test). 
N3 nodal status was associated with the highest 
CD14+B7-H4+ MDSCs values  
Patients without nodal involvement demonstrated the 
lowest number of CD14+B7-H4+ MDSCs both in the 
blood and tumor microcirculation compartment. 
Furthermore, nodal involvement was associated with the 
gradual increase of the CD14+B7-H4+ MDSCs number, 
being the highest in the N3 group (Table 1). There was a 
significant increase in tumor microcirculation number of 
the CD14+B7-H4+ MDSCs compared to that in the blood, 
either when analysed as a group (Table 2, MW test) or in 
particular tumor/blood samples of each patient (Table 2, 
W test). Analysis among groups with different nodal 
involvement demonstrated that N3 group had significantly 
more CD14+B7-H4+ MDSCs than any other group, either 
in blood or tumor (N3 > N0, N3 > N1, N3 > N2) (Table 
3). Additionally, the N2 group also demonstrated a 
significant increase of the CD14+B7-H4+ MDSCs number 
compared to the N0 group, both in blood and tumor 
microcirculation (N2 > N0) (Table 3). 
Higher CD14+B7-H4+ MDSCs values detected in the 
group M0  
Although we detected higher average CD14+B7-H4+ 
MDSCs value in the M0 group (Table 1), a comparison of 
patients between the M0 and the M1 group demonstrated no 
significant difference, either in blood or tumor 
microcirculation samples (Table 3). Comparison of 
blood/tumor average CD14+B7-H4+ MDSCs values 
demonstrated only significant differences in the M1 group 
(Table 2 MW test). Analysis of particular tumor/blood 
samples of each patient demonstrated significant increase of 
the CD14+B7-H4+ MDSCs number in tumor microcirculation 
(Table 2, W test). 
Discussion 
Expression of immunosuppressive B7-H4 molecule 
was widely demonstrated in samples of tumor tissue from 
patients with gynecological malignancies (ovary, uterus), 
as well as in patients suffering from colon and pancreas 
carcinoma 14, 15. In physiological condition, B7-H4 is absent 
from the surface of normal cells 16. Beside malignant cells, 
B7-H4 is extensively detected on the surface of tumor 
infiltrating macrophages with up to 2/3 of the tumor ascites 
Table 3  
Statistical analysis of difference between groups  
of patients according to clinical stage and tumor 
characteristics (Mann Whitney test) 
Group vs. Group Blood Tumor 
Histology type   
   SCLC / Ad NSCLC ns ns 
   SCLC / Sq NSCLC ns 0.0180 
   SCLC / LC NSCLC ns 0.0010 
   Ad NSCLC / Sq NSCLC ns ns 
   Ad NSCLC / LC NSCLC ns ns 
   Sq NSCLC / LC NS-LC ns ns 
Tumor size   
   T1 / T2 0.0029 0.0036 
   T1 / T3 0.0004 0.0056 
   T1 / T4 0.0040 0.0023 
   T2 / T3 ns ns 
   T2 / T4 ns ns 
   T3 / T4 0.0442 ns 
Nodal status   
   N0 / N1 ns ns 
   N0 / N2 0.0452 0.0042 
   N0 / N3 0.0000 0.0002 
   N1 / N2 ns ns 
   N1 / N3 0.0000 0.0137 
   N2 / N3 0.0044 ns 
Metastases   
   M0 / M1 ns ns 
Clinical stage   
   III / IV ns ns 
ns – no significant. 
For other abbreviations see under Table 1. 
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CD14+ macrophages being also B7-H4+ 17, 18. 
More than 10 years ago Ilona Kreyczek group 
demonstrated the importance of B7-H4+ macrophages in 
human ovarian carcinoma 5, 6. They investigated CD14+ 
monocytes, B7-H4- and B7-H4+ macrophages as well as 
regulatory T lymphocytes isolated from fresh tumor 
specimens, tumor induced ascites and blood of 103 patients 
with ovarian carcinoma. Although tumor cells also expressed 
B7-H4 intracellularly, only tumor infiltrating macrophages 
demonstrated surface B7-H4+ expression. This B7-H4+ 
expression was highly inducible, since it was possible to 
transform peripheral blood monocytes with tumor ascites or 
addition of IL-6 and IL-10. Interestingly, IL-4 and 
granulocyte-macrophage colony-stimaluting factors (GM-
CSF) negatively regulate ex vivo and in vitro B7-H4+ 
expression on macrophages. Authors initially concluded that 
the change of local factors concentration, with high IL-6 and 
IL-10, and low IL-4 and GM-CSF resulted in the  
transformation of tumor-associated macrophages toward B7-
H4+ cells. More importantly, Kreyczek et al. 18 further 
demonstrated that B7-H4+ macrophages suppressed in vitro 
activity of T lymphocytes specific for HER2/Neu antigen, in 
a way independent of B7H1 mechanism, arginase or iNOS 
activity. Considering a high number of B7-H4+ macrophages 
detected in tumor-associated ascites, which largely 
outnumbered regulatory T lymphocytes (30% vs. 5%), 
authors concluded that these cells could be principal 
immunosuppressive force, resulting in tumor promotion.  
Matsunaga et al. 19 investigated association of blood 
and tumor CD14+B7H1+ or CD14+B7-H4+ cells with clinical 
and tumor characteristics in the patients with gastric cancer. 
Firstly, they demonstrated that level of B7H1+ or B7-H4+ 
expression is significantly increased on monocytes from 
gastric cancer patients, compared to healthy controls. They 
also found that tumor isolated monocytes expressed 
significantly more B7H1+ or B7-H4+ compared to blood 
monocytes from the same patient, and that the expression of 
these suppressive molecules is directly correlated. Contrary 
to our study, the expression of B7-H4+ directly followed 
HLA-DR expression level on CD14+ cells. Differences come 
from different gating strategies, since our goal was to 
investigate MDSCs which are HLA-DR-/low by definition. 
Anyway, these authors demonstrated significant 
immunosuppressive capacity of CD14+ B7-H4+ cells in vitro 
(reduction of interferon (IFN)-γ secretion by T lymphocytes), 
and also demonstrated that surgical removal of tumor 
resulted in decreased B7-H4+ on circulating CD14+ cells. 
They demonstrated differences in blood and tumor 
CD14+B7H1+ or CD14+B7-H4+ number according to 
histopathology type of gastric cancer, invasion depth, tumor 
size, node involvement, clinical stage and a level of 
lymphovascular invasion. Their data is in accordance with 
the data obtained by our study, indicating that the tumor size 
and the degree of the disease spread is directly associated 
with the number of suppressive CD14+B7-H4+ number. 
Interestingly, their patients in the earlier clinical stage also 
demonstrated insignificantly higher CD14+B7-H4+ number 
compared to later stages. 
Data concerning MDSCs role in patients with lung 
cancer are still limited, especially investigations of B7-H4+ 
MDSCs. 
Investigation of prognostic B7-H4 value in patients 
with NSC-LC conducted as a meta-study by Tan and Shen 20 
indicated significant association of B7-H4 overexpression 
with tumor size, node involvement and the presence of 
metastasis, but without the impact of tumor histology and 
other epidemiological factors. They concluded that B7-H4 
expression is a negative prognostic factor for NSC-LC 
patients. Unfortunately, their study included one big 
imprecision, since in their selection criteria (criteria No 2) 
they included studies with B7-H4 expression detected with 
any method, which implies that they did not differentiate 
expression on malignant tissue or tissue infiltrating 
leukocytes. 
Chen et al. 21 investigated CD14+HLA-DR-/low MDSCs 
frequency in blood samples of almost 80 patients with 
squamous type of LC (Sq NSC-LC). They also demonstrated 
that LC patients had significanlty increased number of these 
cells compared to healthy controls, and that MDSCs number 
gradually rise in those patients with higher TNM stage. In 
favor of immunosuppressive MDSCs impact, they showed 
significantly reduced number of blood CD4+ T and CD8+ T 
lymphocytes in patient samples, as well as the impairment of 
T lymphocyte cytokine secretion in vitro.  
Dendritic cells (DC) isolated from resected tumor tissue 
of NSC-LC patients express other immunosupressive 
molecules, also from B7 family, as B7H3 22. Those DC 
demonstrated severely impaired costimulatory activity 
towards autologous T lymphocytes, produced significantly 
more IL-10 and less IL-12 than controls.  
Huang et al. 23 demonstrated that circulating 
CD14+HLA-DR-/low MDSC are modulators of antitumor 
immune response and were associated with tumor metastasis 
and impaired response to treatment in NSCLC patients 23. 
They evaluated 89 patients with advanced NSCLC. The ratio 
of the CD14+HLA-DR-/low MDSCs, as a percent of total 
CD14+ cells, was significantly higher in NSCLC patients 
compared to healthy controls, and it was proportional to 
clinical stage. Monocytic MDSCs also significantly 
negatively correlated with median progression-free survival 
(p < 0.01). Both the absolute number and percentage of 
CD14+HLA-DR-/low cells were increased in NSCLC patients 
with metastasis, confirming their role in the disease 
progression. Huang et al. 23 also demonstrated that the role of 
CD14+HLA-DR-/low cells in inhibition of T cell function of 
NSCLC patients was mediated by a functional NADPH 
oxidase, as shown by the expression of the oxidase 
component gp91phox and reactive oxygen species (ROS) 
production by these monocytic MDSCs. 
Ex vivo study showed that circulating tumor cell lines 
from SCLC patients induced transformation of peripheral 
blood mononuclear cells (PBMNC) toward diferentiaton of 
monocytes in CD14+ CD163low CD68+ B7-H4+ tumor 
associated macrophages 24. Feng et al. 25 underlined the 
significance of MDSCs in patients with adenocarcinoma LC 
(Ad NSC-LC) positive for epidermal growth for receptor 
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(EGFR) mutation. They also showed that MDSCs number 
(S100A+CD68+) was increased in patient blood samples 
compared to healthy controls. Patients with a poor therapy 
response as well as patients with short progression free 
interval had increased MDSCs number compared to others. 
Again, as in our study, the number of MDSCs was much 
higher in tumor samples compared to matched blood ones. 
A recent study of blood MDSCs subpopulations in the 
NSC-LC patients demonstrated that they were increased in 
number compared to healthy controls, but also showed the 
increased number in a subgroup of COPD as second 
controls 11. The same study showed that MDSCs were more 
frequent in resected tumor tissue than in blood samples of 
these NSC-LC patients. Data from that study demonstrated 
fine differences between LC with different histology. 
Patients with squamous type LC showed the increased 
number of granylocyte like MDSCs compared to the 
adenocarcinoma group, but without differences in 
monocyte like MDSCs. This was in concordance with our 
data, since we showed no significant differences in CD14+ 
MDSCs frequency between NSC-LC patients, but only 
between small cell LC group versus others. On the other 
hand, Yamauchi et al. 11 showed that adenocarcinoma LC 
group had significantly more CD14+B7H1+ MDSCs and 
CD15+B7H1+ MDSCs compared to squamous cell LC 
patients. In our previous study we have demonstrated that 
different histology type of LC is significantly associated 
with particular cytokine profile, either in blood or tumor 
microcirculation samples 26.  
In the study with limited number of NSC-LC patients, 
Pogoda et al. 27 demonstrated that CD14+HLA-DR-
/low MDSCs are not the only population that takes part in 
tumor induced immunosuppression. Beyond MDSCs, they 
showed that CD14+HLA-DR+ monocyte population secreted 
significant amounts of IL-10 in lymph node samples, and IL-
1β and TNF in peripheral blood, lymph nodes and tumor 
tissue. Heuvers et al. 28 investigated MDSCs frequency in 
blood specimens of 185 NSC-LC patients demonstrating the 
increased number of MDSCs, especially granulocyte like, in 
LC patients compared to healthy controls. They also showed 
that the suppression capacity of MDSCs is significantly 
associated with arginase -1 activity.  
The majority of published papers reflect investigations 
in NSC-LC patient population. In a study that involved 42 
SC-LC patients, Tian et al. 29 demonstrated that the absolute 
number and frequency of blood CD14+HLA-DR-/low MDSCs 
were significantly increased in SCLC patients compared with 
those in controls and that the MDSCs frequency correlated 
with tumor stage, serum lactate dehydrogenase (LDH) value 
and shorter overall survival. SCLC patients from our study 
demonstrated the highest average number of CD14+HLA-
DR-/low MDSCs, but in tumor microcirculation samples. 
Conclusion 
We demonstrated a significant association between the 
number of CD14+B7-H4+ MDSCs and the tumor size and 
lymph node involvement. We also showed that LCs of 
different histology dramatically differ in their capacity to 
induce CD14+B7-H4+ MDSCs number, which could be 
interpreted as different immunosuppression potential. We 
found that tumor microcirculation samples are easily 
available for analysis and more important than blood 
samples, offering more sensitive and informative data, more 
precisely reflecting the local balance between tumor and 
immune response. 
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